Clinical Study on the Treatment of Non-alcoholic Fatty Liver Disease with Pingganjian Decoction:A Report of 54 Cases

DING Ronghua; QIAN Junfang; JIANG Juxing

doi:10.13288/j.11-2166/r.2010.03.025

您当前的位置：

首页 >

文章列表页 >

Clinical Study on the Treatment of Non-alcoholic Fatty Liver Disease with Pingganjian Decoction:A Report of 54 Cases

更新时间：2021-11-17

- Clinical Study on the Treatment of Non-alcoholic Fatty Liver Disease with Pingganjian Decoction:A Report of 54 Cases
- Journal of Traditional Chinese Medicine Vol. 51, Issue 3, Pages: 219-222(2010)
- 作者机构：
  
  银川市第二人民医院肝病科
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2010.03.025
  CLC： R259
- Published：2010
- 稿件说明：
移动端阅览
[1]丁荣华,钱俊芳,姜菊星.平肝煎剂治疗非酒精性脂肪肝患者54例临床观察[J].中医杂志,2010,51(03):219-222.

DING Ronghua, QIAN Junfang, JIANG Juxing. Clinical Study on the Treatment of Non-alcoholic Fatty Liver Disease with Pingganjian Decoction:A Report of 54 Cases[J]. Journal of Traditional Chinese Medicine2010, 51(3): 219-222.
[1]丁荣华,钱俊芳,姜菊星.平肝煎剂治疗非酒精性脂肪肝患者54例临床观察[J].中医杂志,2010,51(03):219-222. DOI： 10.13288/j.11-2166/r.2010.03.025.

DING Ronghua, QIAN Junfang, JIANG Juxing. Clinical Study on the Treatment of Non-alcoholic Fatty Liver Disease with Pingganjian Decoction:A Report of 54 Cases[J]. Journal of Traditional Chinese Medicine2010, 51(3): 219-222. DOI： 10.13288/j.11-2166/r.2010.03.025.

摘要

目的评价中药平肝煎剂对非酒精性脂肪性肝病（NAFLD）患者的疗效。方法将符合纳入标准的105例NAFLD患者随机分为治疗组54例和对照组51例。治疗组予平肝煎剂

对照组给予复方益肝灵片、脂必妥片

两组均治疗3个月

观察治疗前后证候积分、体质量指数（BMI）、腰围/臀围比（WHR）、肝脾CT比值、稳态模型胰岛素抵抗指数（HOMA-IR）、肝功能、尿酸和血脂等方面的变化。结果治疗后

治疗组证候积分明显下降

肝脾CT比值明显上升

HOMA-IR水平下降

与对照组比较

差异有统计学意义（P<0.01或P<0.05）。结论中药平肝煎剂治疗NAFLD疗效确切

可能与提高靶组织的胰岛素敏感性、调节机体多代谢紊乱、改善肝脏脂肪沉积有关。

Abstract

Objective To evaluate the effect of Pingganjian Decoction （Decoction for liver diseases） on the non-alcoholic fatty liver diseases （NAFLD）.Methods Totally 105 NAFLD patients were randomized into a treatment group （54 cases） and a control group （51 cases）.The former was treated with Pingganjian Decoction while the latter treated with Fufang Yiganling Tablets and Zhibituo Tablets for 3 months.Changes in the symptoms scores

body mass index （BMI）

waist-hip ratio （WHR）

CT ratio of liver-spleen

homeostasis model assessment insulin resistance （HOMA-IR）

liver functions

uric acid and blood-fat before and after treatment were observed.Results After treatment

in the treatment group

the symptom score was significantly decreased

CT ratio of liver-spleen was significantly increased

and the level of HOMA-IR was decreased.Compared with those of the control group

the difference was significant （P<0.01 or P<0.05）.Conclusion The effect of Pingganjian Decoction on NAFLD is definite.Possibly it relates to the improvement of insulin sensitivity of target organs

the regulation of the disordered metabolism

and the decrease of liver fat deposition.

关键词

Keywords

references

查看原文

Views

269

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and Application of "Source-Pivot-Convergence" Pattern Identification and Treatment Model for Malignant Tumors

Research on the Correlation Between "Tiangui （天癸）" and Female Reproductive Genetic Diseases

Challenges and Recommendations for Implementing Key Technologies in Decentralized Clinical Trials of Traditional Chinese Medicine

LI Guolie's Experience in Treating Orthostatic Hypotension from the Perspective of "Raising the Clear and Directing the Turbid Downward"

Exploration on the Connotation and Application of the Three Aspects of "Dietary Inquiry" for "Appetite" "Eating Capacity" "Food Preference"

Related Author

No data

Related Institution

No data

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰